Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Smoldering Myeloma

Discover more on Smoldering Myeloma with VJHemOnc

VJHemOnc presents The Smoldering Myeloma Channel, featuring the latest developments in this early form of myeloma directly from the experts, including novel investigational approaches, as well as insights into how to mitigate smoldering myeloma progression risk.

Watch a video, listen to our expert podcasts, and explore our latest congress coverage to stay informed on advances in the treatment and management of smoldering myeloma.

Phase II MODIFY trial: isatuximab, iberdomide, and dexamethasone in high-risk smoldering myeloma 3:16
Phase II MODIFY trial: isatuximab, iberdomide, and dexamethasone in high-risk smoldering myeloma
Dean Smith • 25 Sep 2026
Identifying patients who need curative treatment versus disease control in myeloma 3:46
Identifying patients who need curative treatment versus disease control in myeloma
Rahul Banerjee • 24 Sep 2026
Supplement use in MGUS, smoldering myeloma, and multiple myeloma: findings from a patient survey 3:12
Supplement use in MGUS, smoldering myeloma, and multiple myeloma: findings from a patient survey
Urvi Shah • 25 Sep 2026
Long-term outcomes with KRd versus Rd in high-risk smoldering multiple myeloma 4:22
Long-term outcomes with KRd versus Rd in high-risk smoldering multiple myeloma
Dirk van Esser • 24 Sep 2026
Genomic testing in high-risk smoldering myeloma: advice for community hematologists 0:49
Genomic testing in high-risk smoldering myeloma: advice for community hematologists
Francesco Maura • 24 Sep 2026
An NGS liquid biopsy approach vs standard bone marrow FISH for genomic characterization in myeloma 1:33
An NGS liquid biopsy approach vs standard bone marrow FISH for genomic characterization in myeloma
Efstathios Kastritis • 12 Jun 2026
Improving risk stratification methods and patient outcomes in smoldering myeloma 1:55
Improving risk stratification methods and patient outcomes in smoldering myeloma
M. Bakri Hammami • 31 May 2026
ImmunoPRISM results: teclistamab improves depth of response and PFS compared with Rd in HR-SMM 3:34
ImmunoPRISM results: teclistamab improves depth of response and PFS compared with Rd in HR-SMM
Omar Nadeem • 17 Jun 2026
Linvoseltamab demonstrates deep responses in relapsed/refractory multiple myeloma 2:55
Linvoseltamab demonstrates deep responses in relapsed/refractory multiple myeloma
Claudio Cerchione • 11 Jun 2026
Temporal trends in progression risk in smoldering myeloma: insights into a review 2:13
Temporal trends in progression risk in smoldering myeloma: insights into a review
Heinz Ludwig • 14 May 2026
Recent advances and unmet needs in smoldering multiple myeloma 2:00
Recent advances and unmet needs in smoldering multiple myeloma
Kwee Yong • 14 May 2026
Improving risk stratification & early treatment strategies in myeloma and smoldering myeloma 3:05
Improving risk stratification & early treatment strategies in myeloma and smoldering myeloma
Claudio Cerchione • 14 May 2026
CAR-PRISM: cilta-cel in high-risk smoldering multiple myeloma 1:26
CAR-PRISM: cilta-cel in high-risk smoldering multiple myeloma
Irene Ghobrial • 15 May 2026
Advances in risk assessment for smoldering multiple myeloma 2:54
Advances in risk assessment for smoldering multiple myeloma
Irene Ghobrial • 15 May 2026
Early intervention strategies in smoldering myeloma and high-risk MGUS 1:11
Early intervention strategies in smoldering myeloma and high-risk MGUS
Irene Ghobrial • 15 May 2026
Expanding our understanding of the role of the tumor microenvironment in multiple myeloma 13:35
Expanding our understanding of the role of the tumor microenvironment in multiple myeloma
Gareth Morgan et al. • 11 Apr 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals